Found 343 articles for: "Supplement"
FULL SUPPLEMENT: The Role of IL 31 Inhibition in Atopic Dermatitis
September 2026 | Volume 25 | Issue 9 | Department | 154710s1 | Copyright © September 2026
Atopic dermatitis and prurigo nodularis represent the two most burdensome pruritic inflammatory skin diseases encountered in clinical dermatology. While distinct in morphology, chronicity, and epidemi...
Read MoreINDIVIDUAL ARTICLE: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab
September 2026 | Volume 25 | Issue 9 | Supplement Individual Articles | 015471s2 | Copyright © September 2026
Interleukin-31 (IL-31) is a central mediator in atopic dermatitis (AD) and prurigo nodularis (PN), functioning both as the principal pruritogeniccytokine, driving itch through direct...
Read MoreFULL SUPPLEMENT: Real-World Split-Face Case Series of a Phyto Polydeoxyribonucleotide (PDRN) Serum in Integrative Skincare
September 2026 | Volume 25 | Issue 9 | Department | 15490s1 | Copyright © September 2026
Inflammation and photodamage are largely considered the leading contributors to premature skin aging as they lead to decreased collagen content in the skin. Collagen, the most abundant protein in the ...
Read MoreINDIVIDUAL ARTICLE: Real-World Cases Using Phyto Polydeoxyribonucleotide (PDRN) Serum
September 2026 | Volume 25 | Issue 9 | Supplement Individual Articles | 15491s2 | Copyright © September 2026
Background: Integrative skincare refers to a clinician-directed regimen that combines aesthetic procedures with appropriate post-procedure skincare. The novel phyto polydeoxyribo...
Read MoreFULL SUPPLEMENT: Research on Generalized Pustular Psoriasis
August 2026 | Volume 25 | Issue 8 | Department | 63120 | Copyright © August 2026
Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening disease of immunologic dysfunction. The pathophysiology of the disease was not well understood until recently. As a...
Read MoreINDIVIDUAL ARTICLE: Generalized Pustular Psoriasis: A Contemporary Review of Diagnosis, Pathophysiology, and IL-36 Pathway-Directed Management
August 2026 | Volume 25 | Issue 8 | Supplement Individual Articles | 63121 | Copyright © August 2026
Observations: Emerging epidemiologic, clinical, and real-world data establish GPP as a distinct disease entity associated with high rates of hospitalization, multisystem involvem...
Read MoreFULL SUPPLEMENT: Emerging Topical Approaches in the Management of Female Pattern Hair Loss
June 2026 | Volume 25 | Issue 6 | Department | 83250s1 | Copyright © June 2026
Alopecia can be categorized as cicatricial and non-cicatricial, with female androgenetic alopecia (AGA) and female pattern hair loss (FPHL) included in the latter category....
Read MoreINDIVIDUAL ARTICLE: Efficacy of a Dual-Serum Cosmetic System in Women With Female Pattern Hair Loss
June 2026 | Volume 25 | Issue 6 | Supplement Individual Articles | 83251s3 | Copyright © June 2026
Read MoreFULL SUPPLEMENT: Mechanism Matters: IL-17 Receptor Blockade With Brodalumab and Its Role in Durable Psoriasis Clearance and Fast Onset of Action
May 2026 | Volume 25 | Issue 5 | Department | 15470s1 | Copyright © May 2026
Psoriasis is a chronic immune-mediated inflammatory disease driven by dysregulated interleukin-17 (IL-17) signaling across skin and musculoskeletal tissues. While upstream IL-23 inhibition and selecti...
Read MoreINDIVIDUAL ARTICLE: Clinical and Real-World Implications of IL-17 Receptor Blockade in Plaque Psoriasis and Psoriatic Arthritis With Brodalumab
May 2026 | Volume 25 | Issue 5 | Supplement Individual Articles | 15471s3 | Copyright © May 2026
Brodalumab is a fully human monoclonal antibody targeting interleukin-17 receptor A (IL-17RA), providing a mechanistically distinct approach to inhibiting IL-17–mediated inflammation in pla...
Read MoreFULL SUPPLEMENT: 2025 Poster Abstracts Supplement
April 2026 | Volume 25 | Issue 4 | Department | 269616s1 | Copyright © April 2026
Over the past two decades, the Skin of Color Update meeting has been dedicated to delivering continuing medical education to dermatologic audiences that highlights best practices and evolving trends i...
Read MoreFULL SUPPLEMENT: Real World Cases of a Novel Topical Tranexamic Acid Serum in Treatment of Hyperpigmentation
April 2026 | Volume 25 | Issue 4 | Department | 154700s3 | Copyright © April 2026
Hyperpigmentation and dyschromia are amongst the most common dermatologic concerns for patients seeking care.1 They can affect patients of all skin types and ages, and most commonly occurs ...
Read MoreINDIVIDUAL ARTICLE: Real World Use of Topical Tranexamic Acid Serum in Patients With Hyperpigmentation
April 2026 | Volume 25 | Issue 4 | Supplement Individual Articles | 154701s3 | Copyright © April 2026
Hyperpigmentation and pigmentary alterations are common dermatologic concerns that remain difficult to treat. The modernized topical tranexamic acid serum (TNXA-SHOT) is a novel, patent-pending s...
Read MoreFULL SUPPLEMENT: Pre-, Intra-, and Postprocedure Skincare
March 2026 | Volume 25 | Issue 3 | Department | s1 | Copyright © March 2026
Amanda is a 35-year-old, Black woman currently working as a law firm secretary. She denies being a smoker and does n...
Read MoreINDIVIDUAL ARTICLE: Tailored Touch: Test Your Knowledge on Pre-, Intra-, and Postprocedure Skincare—Based on a Medscape Education Online Activity
March 2026 | Volume 25 | Issue 3 | Supplement Individual Articles | s4 | Copyright © March 2026
Variations in the prevalence, clinical presentation, and approach to treatment of aesthetic dermatologic conditions are observed in patient populations with skin of color (SOC). A heightened pred...
Read MoreFULL SUPPLEMENT: A Novel Oral Treatment for Psoriasis: Deucravacitinib
February 2026 | Volume 25 | Issue 2 | Department | 070211s1 | Copyright © February 2026
INDIVIDUAL ARTICLE: Evidence-Based Synthesis of Deucravacitinib: Long Term Efficacy, Safety, and Practical Use in Moderate-to-Severe Psoriasis
February 2026 | Volume 25 | Issue 2 | Supplement Individual Articles | 070210s3 | Copyright © February 2026
Background: Deucravacitinib, a first-in-class, oral, selective TYK2 inhibitor, has redefined systemic therapy options for moderate-to-severe plaque psoriasis. This review synthes...
Read MoreFULL SUPPLEMENT: Nordic European Cutaneous Oncodermatology Management (Necom) 7: Real-World Cases Applying Recommendations for the Prevention and Treatment of Skin Reactions Related to Cancer Therapies Using Skin-Protective Measures
December 2025 | Volume 24 | Issue 12 | Department | 508410s1 | Copyright © December 2025
The current risk of getting cancer before age 80 in Nordic countries is estimated at 42.7% in males and 36.2% in females. Based on the collaborative Nordic cancer registry (NORDCAN), breast, lung, and...
Read MoreINDIVIDUAL ARTICLE: NECOM 7: Real-World Cases on Preventive and Treatment Using Skin Care for Cancer Treatment-Related Skin Reactions
December 2025 | Volume 24 | Issue 12 | Supplement Individual Articles | 50842s3 | Copyright © December 2025
As cancer prevalence continues to increase in Nordic countries, the amount of dermatological adverse events, termed cutaneous adverse events (cAEs), will also increase. The Nordic European Cutane...
Read MoreError: 500: HTTP/2 500INDIVIDUAL ARTICLE: The Dark Side of Oral Antibiotics: Adverse Events of Consideration in Dermatology
November 2025 | Volume 24 | Issue 11 | | s4 | Copyright © November 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
